Abstract

A targeted and timely treatment can be a beneficial tool for patients with hematological emergencies (particularly acute leukemias). The key challenges in the early diagnosis of leukemias and related hematological disorders are their symptom-sharing nature and prolonged turnaround time as well as the expertise needed in reporting confirmatory tests. The present study made use of the potential morphological and immature fraction-related parameters (research items or cell population data) generated during complete blood cell count (CBC), through artificial intelligence (AI)/machine learning (ML) predictive modeling for early (at the pre-microscopic level) differentiation of various types of leukemias: acute from chronic as well as myeloid from lymphoid. The routine CBC parameters along with research CBC items from a hematology analyzer in the diagnosis of 1577 study subjects with hematological neoplasms were collected. The statistical and data visualization tools, including heat-map and principal component analysis (PCA,) helped in the evaluation of the predictive capacity of research CBC items. Next, research CBC parameter-driven artificial neural network (ANN) predictive modeling was developed to use the hidden trend (disease’s signature) by increasing the auguring accuracy of these potential morphometric parameters in differentiation of leukemias. The classical statistics for routine and research CBC parameters showed that as a whole, all study items are significantly deviated among various types of leukemias (study groups). The CPD parameter-driven heat-map gave clustering (separation) of myeloid from lymphoid leukemias, followed by the segregation (nodding) of the acute from the chronic class of that particular lineage. Furthermore, acute promyelocytic leukemia (APML) was also well individuated from other types of acute myeloid leukemia (AML). The PCA plot guided by research CBC items at notable variance vindicated the aforementioned findings of the CPD-driven heat-map. Through training of ANN predictive modeling, the CPD parameters successfully differentiate the chronic myeloid leukemia (CML), AML, APML, acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), and other related hematological neoplasms with AUC values of 0.937, 0.905, 0.805, 0.829, 0.870, and 0.789, respectively, at an agreeably significant (10.6%) false prediction rate. Overall practical results of using our ANN model were found quite satisfactory with values of 83.1% and 89.4.7% for training and testing datasets, respectively. We proposed that research CBC parameters could potentially be used for early differentiation of leukemias in the hematology–oncology unit. The CPD-driven ANN modeling is a novel practice that substantially strengthens the predictive potential of CPD items, allowing the clinicians to be confident about the typical trend of the “disease fingerprint” shown by these automated potential morphometric items.

Highlights

  • Artificial intelligence (AI) has seen remarkable development and increased value during the past two decades along with its successful introduction for solving complex data-related problems [1]

  • The study population consisted of newly diagnosed acute leukemia cases that were presented to the academic research center (National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan) from February 2014 to December 2020

  • In the final reports from diagnostic work-ups, all cases were allocated to one of the six principle disease groups and 354, 96, 213, 272, 153, and 489 cases were of acute myeloid leukemia (AML), acute promyelocytic leukemia (APML) PML-RARA, chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), and ‘others (’Non-Hodgkin’s lymphoma, Plasma cell dyscrasia, and etc.), respectively

Read more

Summary

Introduction

Artificial intelligence (AI) has seen remarkable development and increased value during the past two decades along with its successful introduction for solving complex data-related problems [1]. In recent years, a significant increase in this trend has been noted for the use of AI in clinical aims for all three conventional medical tasks: diagnosis, therapy, and prognosis, but comparatively more for diagnosis [2,3]. A major question is whether ML will prove itself as an applied clinical tool in medical diagnostics. Through a brief literature survey, we can find various studies regarding successful applications of the ML approach in specialized diagnostic fields [4,5,6,7,8]. For complex fields of clinical diagnostics such as hematology, limited examples of successful applications of ML have been reported

Methods
Findings
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.